ABSTRACT The immunohistochemical localization of guanylate cyclase [GTP pyrophosphate-lyase (cyclizing), EC 4.6.1.2] has been examined in rat neocortex, caudate-putamen, and cerebellum by using specific monoclonal antibodies. Immunofluorescence could be seen within somata and proximal dendrites of neurons in these regions. A nuclear immunofluorescence reaction to guanylate cyclase was characteristically absent. Guanylate cyclase [GTP pyrophosphate lyase (cyclizing), EC 4.6.1.2] catalyzes the formation of guanosine 3',5'-monophosphate (cyclic GMP) from GTP. Two forms of the enzyme, one soluble and the other membrane-associated, have been described in most tissues studied (1). Characterization of the enzyme in murine brain (2) demonstrates comparable enzyme activity in the neocortex and cerebellum and highest total guanylate cyclase activity in the caudate-putamen complex. Subcellular fractionation ofmouse (2) and rat (3) caudate-putamen homogenates shows the specific activity of the soluble form of the enzyme to be greater than that of the particulate fraction. It has been hypothesized that cyclic GMP has an important role in the mediation of cholinergic-muscarinic receptor actions (4-7), glutamate neurotransmission (8), and the generation of seizure activity (9) in the nervous system.
Guanylate cyclase [GTP pyrophosphate lyase (cyclizing), EC 4.6.1.2] catalyzes the formation of guanosine 3',5'-monophosphate (cyclic GMP) from GTP. Two forms of the enzyme, one soluble and the other membrane-associated, have been described in most tissues studied (1) . Characterization of the enzyme in murine brain (2) demonstrates comparable enzyme activity in the neocortex and cerebellum and highest total guanylate cyclase activity in the caudate-putamen complex. Subcellular fractionation ofmouse (2) and rat (3) caudate-putamen homogenates shows the specific activity of the soluble form of the enzyme to be greater than that of the particulate fraction. It has been hypothesized that cyclic GMP has an important role in the mediation of cholinergic-muscarinic receptor actions (4) (5) (6) (7) , glutamate neurotransmission (8) , and the generation of seizure activity (9) in the nervous system.
Another experimental approach, immunohistochemical localization of cyclic GMP in various brain regions, has demonstrated accumulation of this cyclic nucleotide in neuroglia (10, 11) , in stellate and basket neurons of the cerebellum (10) , in postganglionic neurons of the superior cervical ganglion (12, 13) , and predominantly within neurons ofthe caudate-putamen and the neocortex (14) . Immunocytochemistry in the latter regions demonstrated cyclic GMP accumulation at the subsynaptic terminal density and adjacent cytoplasm in type 1 synapses (14) . Cyclic GMP has been proposed to exert its physiological actions through phosphorylation of a cyclic GMP-dependent protein kinase (15) . Cyclic GMP-dependent protein kinase activity is extremely elevated in the cerebellum (16) , and immunohistochemical localization of this enzyme has been demonstrated within Purkinje cells and their processes (17) . Cyclic GMP phosphodiesterase (EC 3.1.4.17), the enzyme that hydrolyzes cyclic GMP to 5'-GMP, has been detected cytochemically at the subsynaptic density of axospinous synapses of the rat caudate-putamen complex and neocortex (18) . A preferential localization of soluble guanylate cyclase in neurons has been described in disrupted rat brain (19) and after kainic acid production of lesions of the rat caudate-putamen (3).
The present work describes the immunohistochemical localization of guanylate cyclase in three central nervous system areas by using four different monoclonal antibodies directed against the soluble form of rat lung enzyme. The antibodies crossreact avidly with soluble guanylate cyclase from all rat tissues examined, including brain, and may partially interact with the particulate enzyme form (20) . Specific localization of guanylate cyclase was determined by using the fluorescein doubleantibody technique (21) . The enzyme was visualized within the cytoplasm and proximal dendrites of neurons of the rat caudate-putamen, neocortex, and cerebellum. In addition, the immunohistochemical localization of cyclic GMP and cyclic AMP was concurrently visualized in these same regions. METHODS Male Sprague-Dawley rats (200-250 g) provided experimental tissue. Animals were decapitated, the brain was removed en toto, and a coronal block was made caudal to the hypophyseal stalk. The cut surface was frozen to a brass mounting chuck and stored at -25°C in a cryostat. Coronal 6-to 8-,um sections of the rostral caudate-putamen complex and overlying neocortex at the level of +3.4 mm, according to the brain atlas of Pellegrino et al (22) The monoclonal antibodies bound to guanylate cyclase were visualized by application of an appropriate secondary fluorescein isothiocyanate conjugate of goat anti-mouse IgG (y-chain specific) or IgM (,u-chain specific) (Cappel Laboratories, Cochranville, PA) for 1 hr at 4°C at a 1:100 dilution. Unbound secondary antibody was washed off the slides with PJNaCl. Slides were dried and viewed under glycerol immersion at X25.
Abbreviation: Pj/NaCl, phosphate-buffered saline.
The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 Antibody production and specificity has been described (20, 23) . The four monoclonal antibodies used in the study, designated B1, B2, B4, and D1, have been characterized in detail. Antibodies B1, B2 and B4 are of the IgG1 subclass, and D1 is an IgM. Prior studies examining the interaction of crude tissue extracts with the antibodies immobilized on solid supports have demonstrated that all four antibodies specifically recognize soluble guanylate cyclase from a variety of tissues (24) .
The specificity of staining for guanylate cyclase was tested with the following controls: (i) use of a control monoclonal antibody (i.e., no anti-guanylate cyclase activity) as a primary antibody; this IgG1 antibody was used at the same concentration as the specific monoclonal antibodies; (ii) use ofnonimmunized mouse immunoglobulin for the primary antibody; (iii) prior incubation of anti-guanylate cyclase antibodies with purified guanylate cyclase (30 min at 37TC, followed by 12 hr at 4QC) and subsequent immunohistochemical processing using a 1:100 dilution; and (iv) increasing dilutions ofthe anti-guanylate cyclase antibodies from 0.1 ,ug/ml through 0.0001 ,ug/ml in PjNaCl.
The staining reaction was considered specific when no immunofluorescence resulted after any of these four treatments. The immunohistochemical methodological control was application of goat anti-mouse IgG or goat anti-mouse IgM (Cappel Laboratories, Cochranville, PA) at 1:10 through 1:1000 dilutions in PJNaCl for 8-22 hr at 4°C. 'a Cyclic GMP and cyclic AMP antisera were raised in rabbits according to the method described by Spruill and Steiner (21) and have been extensively characterized (13, 14) . These antisera were used at a dilution of 1:500 in PJNaCl for 10-22 hr at 4°C within somata and proximal dendrites ofneurons in these brain regions. Elements demonstrating guanylate cyclase immunoreactivity in the caudate-putamen (Fig. 1A) correspond in size and dimensions to the medium spiny neuron (25) . The identification of these cells was confirmed by using toluidine blue counterstain. The larger pyramidal neurons of layers 3 and 5 of the neocortex and their apical dendrites (wide arrows, Fig. 1C ) were reactive in guanylate cyclase immunohistochemistry. The identification of the positively fluorescent elements was based on toluidine blue counterstaining and the distinct cytoarchitecture of this neuronal type (26) . Purkinje cells and their primary dendritic tree were readily discerned as containing guanylate cyclase immunoreactivity (Fig. 2a) . Immunofluorescence staining was also apparent within stellate and basket neurons ofthe granular layer. Toluidine blue counterstain (Fig. 2c) demonstrates all of the cells present in the field and illustrates the identity of the various cell types. Nuclear staining was characteristically absent in the reactive cells in all experimental tissue examined. Qualitatively similar staining patterns were observed after immunohistochemistry with all four different monoclonal antibodies. The fluorescence pattern seen in guanylate cyclase immunohistochemical assessment was coincident with cyclic GMP localization in these central nervous system areas ( Fig. 1 B and D) . In addition to its neuronal localization, cyclic GMP immunoreactivity could also be seen within processes of fibrous astrocytes (arrows in Fig. 1 B and D) , and in Bergmann glia of the cerebellum (data not shown; ref. 11 ), but this cellular element was not reactive for guanylate cyclase. There are several explanations for this disparity. Astrocytes may absorb cyclic GMP from the extracellular milieu, and therefore the nucleotide may not be synthesized in these cells. Alternatively, astrocytes may contain predominately particulate guanylate cyclase that is not being detected by the antibodies.
Immunofluorescence was abolished when the monoclonal antibodies were first exposed to purified guanylate cyclase as described in Methods (Fig. 2b) . The molar enzyme-to-antibody ratio was 5. Specific guanylate cyclase staining was also absent when control monoclonal antibody (i.e., no anti-guanylate cyclase immunoreactivity) was used as the primary antibody (Fig.  3) . Immunohistochemical staining for cyclic AMP was quite different from either cyclic GMP or guanylate cyclase. Fluorescent staining for this cyclic nucleotide was uniformly observed in both neuronal and glial elements (data not shown). DISCUSSION Immunohistochemical methods have been used to determine the cellular localization of guanylate cyclase in intact brain tissue. Four monoclonal antibodies, all of which have been well characterized (refs. 20, 23 , and 24 and Methods), were used to visualize the distribution of the enzyme. Although the antibodies were produced against the soluble rat lung enzyme, all have been demonstrated previously to crossreact with the soluble brain enzyme by using immunoprecipitation (20) . In addition, competitive binding experiments have demonstrated recently that the four monoclonal antibodies are distinct and recognize several different specific determinants on the enzyme (ref. 24 and unpublished observations). Thus, the observation that all three IgG and the IgM monoclonal antibodies give similar qualitative immunofluorescent staining patterns is strong evidence that they are specifically staining guanylate cyclase. Furthermore, the numerous controls reported here substantiate the specificity of the immunohistochemical method.
The localization of guanylate cyclase was within neuronal perikarya and proximal dendrites of the rat caudate-putamen Neurobiology: Ariano. et a! complex, neocortex, and cerebellum. Definitive identification ofthese cell types in this heterogeneous tissue has been accomplished through the use of toluidine blue counterstain and the characteristic cytoarchitecture of the neurons previously described by using the Golgi technique for these three brain regions (25) (26) (27) (20) . Furthermore, the degree of crossreactivity is increased when the particulate enzyme is immobilized (e.g., on a solid support or membrane). Therefore, it is possible that we are measuring particulate enzyme as well as the soluble enzyme that remains after tissue preparation. Immunocytochemical data, along with specific antisera to the particulate enzyme form, are required to resolve this issue. At present, it can be concluded only that we are visualizing a pool of enzyme that correlates in part with intracellular pools of cyclic GMP. Further, the predominantly neuronal location ofcyclic GMP, cyclic GMP phosphodiesterase, cyclic GMP-dependent protein kinase, and guanylate cyclase suggest a role for cyclic GMP in
